Study Of Indirect Fibromarkers inIdentifying theDegree ofLiver Fibrosis During Antiviral Therapy Of Patients With Hepatitis HCV Etiology

Authors

  • Bayjanov A.K
  • Nasirova Х.P Center for the development of professional qualification of medical workers
  • Khikmatullaeva A.S Research Institute of Virology of the Republican specialized scientific and practical medical center of epidemiology, microbiology, infectious and parasitic diseases
  • Abdukadirova M.A Center for the development of professional qualification of medical workers
  • Yarmukhamedova N.A Center for the development of professional qualification of medical workers
  • Raximova V.Sh Research Institute of Virology of the Republican specialized scientific and practical medical center of epidemiology, microbiology, infectious and parasitic diseases
  • Brigida K.S. Research Institute of Virology of the Republican specialized scientific and practical medical center of epidemiology, microbiology, infectious and parasitic diseases
  • Ibadullaeva N.S Center for the development of professional qualification of medical workers
  • Mirrakhimova N.M Research Institute of Virology of the Republican specialized scientific and practical medical center of epidemiology, microbiology, infectious and parasitic diseases
  • Каn N Research Institute of Virology of the Republican specialized scientific and practical medical center of epidemiology, microbiology, infectious and parasitic diseases
  • Matyakubova Feruza Egamovna Samarkand State Medical University

DOI:

https://doi.org/10.62480/tjms.2024.vol37.pp7-12

Keywords:

hepatitis C virus, fibrosis, APRI

Abstract

This  work  examined  the  diagnostic  role  of  biomarkers -APRI, alpha-fetoprotein–AFP  and gammaglutamine transpeptidase–GGTP before and after antiviral therapy in patients with different degrees of liver fibrosis. At the same time, there was a decrease in these indicators after treatment, which indicates a reverse development of liver fibrosis after specific therapy.During therapy, a significant decrease in APRI from 0.67 to 0.33 (p<0.05), AFP from 4.82 to 1.77 (p<0.01) and GGTP from 42.4 to 26.8 was established (p<0.05).  Thus,  APRI,  AFP  and  GGTP  indicators  can  be  used  as  dynamic  markers  for  assessing  the antifibroticeffect of etiotropic therapy for hepatitis C

References

Аfdhal N., Everson G.T., Calleja J.L.et al. Effect of viral suppression on hepatic venouspressure gradient in hepatitis C with cirrhosis and portal hypertension.J. Viral. Hepat,2017. -No 24(10). –С. 823-831.2.Antonini T. M., Coilly A., Rossignol E. et al. ANRS C023 CUPILT study group. Sofosbuvir-based regimens in HIV/HCV coinfected patients after liver transplantation: results from the ANRS CO23 CUPILT study. Transplantation, 2018. –N 102(1). -Р. 119-126. 3.Foster G. R., Pianko S., Brown A. et al. BOSON Study Group. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology, 2015. –N 149(6). –P. 1462-1470.4.Ganesan M. К. Matrix stiffness regulate apoptopiccell death in HIV-HCV co-infected hepatocytes: Importance for liver fibrosis progression. Biochem Biophys Res Commun, 2018. –N 500. –P. 717-722.5.Hеzode C. Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients with HCV Genotype 1 Infection and Cirrhosis / Gastroenterology, 2014. -V. 147. -No 1. -P. 132-142.6.Konerman M. A., Mehta S. H., Sutcliffe C. G. et al. Fibrosis progression in human immunodeficiency virus/hepatitis Сvirus coinfected adults: prospective analysis of liver biopsy pairs. Hepatology, 2014. -V.59. -N3. -P. 767-775. 7.Lafeuillade A. Eliminating the HIV reservoir. Curr HIV/AIDS Rep., 2012. Jun. –N. 9 (2). –P. 121-131.8.Lo Re V., Kallan M. J., Tate J. P. et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study // Ann Intern Med., 2014. Mar 18. -Vol. 160 (6). -Р. 369-379. doi: 10.7326/M13-1829.9.Poordad F., Schiff E. R., Vierling J. M. еt al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology, 2016. –N 63(5). –P. 1493-1505.10.Roger Ch., Ngoc W. Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection. Ann Intern Med, 2013. -Vol. 158. –N 11. –P. 807-820.11.Sulkowski M. S. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients coinfected with HIV-1: a randomized trial. JAMA, 2015. -Vol. 313 (12). -Р223-1231.12.Terilli R. R., Cox A. L. Immunity and hepatitis C: a review. Curr. HIV/AIDS Rep., 2013. -Vol. 10. -N 1. –Р. 51-58.

Downloads

Published

2024-10-28

Issue

Vol. 37 (2024): TJMS

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

User Rights

Under the Creative Commons Attribution-NonCommercial 4.0 International (CC-BY-NC), the author (s) and users are free to share (copy, distribute and transmit the contribution).

Rights of Authors

Authors retain the following rights:
1. Copyright and other proprietary rights relating to the article, such as patent rights,
2. the right to use the substance of the article in future works, including lectures and books,
3. the right to reproduce the article for own purposes, provided the copies are not offered for sale,
4. the right to self-archive the article.

How to Cite

Study Of Indirect Fibromarkers inIdentifying theDegree ofLiver Fibrosis During Antiviral Therapy Of Patients With Hepatitis HCV Etiology. (2024). Texas Journal of Medical Science, 37, 7-12. https://doi.org/10.62480/tjms.2024.vol37.pp7-12